^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    β-catenin antagonist

    Related drugs:
    over1year
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Recruiting, Sapience Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    ST316
    over1year
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=156, Not yet recruiting, Sapience Therapeutics
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    ST316
    almost2years
    Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin (AACR 2023)
    Anti-tumor activity was accompanied by an increase the M1/M2 ratio. Overall, these results support the immuno-therapeutic potential of ST316 and extend the application range of ST316 to include Wnt-driven cancers with poor clinical response to immune checkpoint blockade and other immunotherapeutic agents.
    Late-breaking abstract • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD163 (CD163 Molecule) • BCL9 (BCL9 Transcription Coactivator) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    ST316